New discovery by Tamir Biotech may offer cure for human papillomavirus

USA-based Tamir Biotechnology  (Pink Sheets: ACEL) - formerly Alfacell - says that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of its lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV). Testing was performed using the HPV 11 strain, which along with HPV type 6, is responsible for ninety percent of genital or anal warts.

According to the scientist performing the test, the results were among the top 1%-2% seen by the researcher for testing of HPV type 11. The report states: "Excellent antiviral activity and no cellular toxicity at doses tested."

Within the last several months, Tamir has reported significant results for its compounds against Dengue Fever, Yellow Fever, SARS, CMV, and now HPV. The firm says it is “on the cusp of building an impressive antiviral portfolio that will be targeting viruses where there is currently an unmet need. Besides the fact that our drugs have shown significant antiviral activity against the viruses mentioned above, equally impressive is the fact that very low concentrations of our drugs were needed in order to show this significant antiviral activity.”